Physician profile
Dany H Zayour
NPI 1952523276
$743,990.44
in general payments reported to CMS, 2019-2025
53 companies · $154K in 2025
The $154K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $70K · 2021: $36K · 2022: $119K · 2023: $100K · 2024: $113K · 2025: $154K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $316K · Travel and Lodging: $38K · Food and Beverage: $12K · Consulting Fee: $650 · Education: $89.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $316,055.69 |
| Travel and Lodging | $38,422.23 |
| Food and Beverage | $11,868.80 |
| Consulting Fee | $650.00 |
| Education | $89.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $429,394.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $213,985.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $22,931.90 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,393.94 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $12,240.33 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $10,333.86 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $8,309.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $8,215.24 | 2019-2020 | |
| Dexcom, INC. | $4,798.04 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $2,725.55 | 2019-2025 | Synthroid, Linzess, Viberzi |
| Amgen INC. | $971.60 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $931.17 | 2020-2025 | Freestyle Libre 3, Afinion 2, Freestyle Libre 2 |
| Corcept Therapeutics | $650.83 | 2019-2025 | Korlym |
| Medtronic Minimed, INC. | $635.72 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $486.70 | 2021-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $482.65 | 2020-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $459.80 | 2021-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $405.59 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Medtronic, INC. | $388.60 | 2021-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $333.30 | 2021-2025 | |
| Amarin Pharma, INC. | $314.28 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $269.78 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Esperion Therapeutics, INC. | $228.61 | 2020-2021 | |
| Pfizer INC. | $218.86 | 2019-2025 | |
| Radius Health, INC. | $207.39 | 2019-2025 | Tymlos |
| Astellas Pharma US INC | $162.24 | 2023-2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $138.74 | 2021-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $136.29 | 2019-2025 | Unithroid |
| Neurocrine Biosciences, INC. | $127.26 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $112.35 | 2021-2025 | Nexletol, Contrave |
| Ascensia Diabetes Care US INC. | $106.52 | 2022-2023 | |
| Amryt Pharma Holdings Ltd | $98.22 | 2021-2022 | |
| Ibsa Pharma INC. | $84.53 | 2019-2025 | Tirosint, Tirosint, Flector |
| Eusa Pharma (US) LLC | $76.79 | 2022 | |
| Horizon Therapeutics Plc | $71.73 | 2023 | Tepezza |
| Chiesi USA, INC. | $68.14 | 2024-2025 | Mycapssa, Myalept |
| Nevro Corp. | $59.92 | 2022-2023 | Senza |
| Madrigal Pharmaceuticals | $55.96 | 2025 | Rezdiffra |
| Clarus Therapeutics INC. | $53.30 | 2021 | |
| Aimmune Therapeutics, INC. | $51.16 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $45.37 | 2021-2023 | Somatuline Depot |
| Cequr Corporation | $42.99 | 2024 | Cequr Simplicity |
| Averitas Pharma INC. | $25.95 | 2023 | Qutenza |
| Vivus LLC | $21.60 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.96 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.17 | 2021 | |
| Almatica Pharma LLC | $16.84 | 2024 | Loreev Xr |
| Tandem Diabetes Care, INC. | $15.16 | 2020 | |
| Kyowa Kirin, INC. | $14.81 | 2024 | Crysvita |
| Shire North American Group INC | $14.67 | 2019 | |
| Tolmar, INC. | $14.57 | 2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $13.12 | 2021 | |
| Glaxosmithkline, LLC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dany Zayour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.